Dr. Lal PathLabs Limited records growth of 17.7% in Q1 FY2016-17

New Delhi, July 30, 2016: Dr. Lal PathLabs Limited (referred to as the “Company”; NSE: LALPATHLAB, BSE: 539524), a leading diagnostic and related healthcare service provider announces their financial results for the quarter ended June 30, 2016

Consolidated Performance Highlights: Q1FY2016-17 vs. Q1FY2015-16

· Operating Revenue increased by 17.7% Y-o-Y to Rs. 2228 million vs Rs 1893 million in the previous year. Underlying volume growth is 15%

· EBITDA increased by 22.7% Y-o-Y to Rs.604 million from Rs 492 million in the same quarter last year. Normalised EBITDA increased by 17.3% after adjusting for ESOP provisions in PY financials.

· EBITDA Margin was 27.1% for Q1 2016 vs 26% in Q1 2015

· Profit after Tax increased by 29.7% to Rs. 402 million from Rs 310 million; Margins of 18% vs 16.4% last year in Q1

Commenting on the results and performance, Dr. Arvind Lal, Chairman and Managing Director

said:

I am delighted to share the Q1 2016 financial and operating results of the Company which have shown a healthy growth of nearly 18%. I am pleased to inform that our persistent pursuit and efforts to grow our brand and provide better diagnostic services to a nation where there is an immense and urgent need for quality healthcare, has translated in us not only fulfilling our passion but has also generated positive results. Our continuous initiatives to innovate and expand have enabled us stay ahead on our growth curve, in a sector which we believe is highly dynamic and competitive

I am happy to announce that the business has grown in June Quarter 20 16 to a revenue of Rs 2228 mn. The PAT has grown to Rs 402 mn with a margin of 18%.

The revenue growth was driven by 15% volume growth in Q1 2016

We are confident that with the support and commitment of our teams we will continue to deliver high quality services to our patients and drive growth and create significant value for all our stakeholders.

Financial Overview (Consolidated)

Rs. Mn

Particulars	JQ’16	JQ’15	Gr %
Total Revenue	2,228.4	1,893.1	17.7%
Total Expenditure	1,624.3	1,378.5	17.8%
ESOP	–	22.5
EBITDA	604.0	492.1	22.7%
Margins	27.1%	26.0%
PBT	599.3	468.3	28.0%
Margins	26.9%	24.7%
PAT	401.7	309.8	29.7%
Margins	18.0%	16.4%
EPS (Diluted)	4.8	3.7	28.5%

Corporate Comm India(CCI Newswire)